作者: Nenad Sarapa
DOI: 10.1007/978-1-59259-884-7_8
关键词:
摘要: Ever since it was introduced in routine clinical cardiology practice (1), the continuous ambulatory electrocardiogram (Holter ECG) has been routinely used for diagnostic assessment of patients with different types heart disease like cardiac arrhythmias, transient ischemic episodes and silent myocardial ischemia. The incidence arrhythmia ischemia, as well rate variability on Holter ECG acquired continuously over 24 h or longer have useful predicting outcomes (2, 3, 4, 5). Likewise, is often drug research monitoring general safety novel drugs under development, particularly during early phase I trials. In contrast, only rarely development formal drug-induced effects repolarization, experience central laboratories measuring intervals limited. Pharmaceutical sponsors alike would benefit if reliable QT/QTc were possible by ECG, whereby digital 12-lead be to substitute standard resting supine ECGs prolongation.